This article is an erratum on:
Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis
Frontiers Production Officeby Ma J and Ge Z (2021). Front. Pharmacol. 12:701690. doi: 10.3389/fphar.2021.701690
Due to a production error, there was a mistake in the legends for Figures 6–8 as published. The legend of Figure 6 matches the graph of Figure 7, the legend of Figure 7 matches the graph of Figure 8, and the legend of Figure 8 matches the graph of Figure 6. The correct legends appear below. The publisher apologizes for this mistake.
FIGURE 6
FIGURE 6. Forest plot of efficacy represents the direct and indirect comparison.
FIGURE 7
FIGURE 7. Forest plot of grade 3/4 adverse events of azacitidine vs. conventional care regimens (direct evidence-RR).
FIGURE 8
FIGURE 8. Forest plot of grade 3/4 adverse events of decitabine vs. conventional care regimens (direct evidence-RR).
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: decitabine, azacitidine, acute myeloid leukemia, higher-risk myelodysplastic syndrome, network meta-analysis
Citation: Frontiers Production Office (2023) Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis. Front. Pharmacol. 14:1213053. doi: 10.3389/fphar.2023.1213053
Received: 27 April 2023; Accepted: 27 April 2023;
Published: 05 May 2023.
Approved by:
Frontiers in Pharmacology Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn